RUNX1 and acute myeloid leukemia: The survival analysis on basis of two AML cohorts disclosed that upregulation of GCNT2 conferred an adverse outcome in AML; data from the TCGA cohort indicated that high-expressed GCNT2 correlated with multiple adverse phenotypes, such as lower HB, older age, complex karyotype, RUNX1 and NRAS mutations, and patients with GCNT2low tended to have more incidence of CEBPA mutation regarding as a favorable biomarker; besides, patients with FAB-M4,5 were more frequent with high GCNT2 expression in accordance with the observation above that expression of GCNT2 was reserved in the monocytes.